Currently, there are 128.76M common shares owned by the public and among those 125.07M shares have been available to trade.
The company’s stock has a 5-day price change of -48.85% and -55.98% over the past three months. PCVX shares are trading -53.87% year to date (YTD), with the 12-month market performance down to -44.88% lower. It has a 12-month low price of $58.10 and touched a high of $121.06 over the same period. PCVX has an average intraday trading volume of 1.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -46.70%, -52.29%, and -57.60% respectively.
Institutional ownership of Vaxcyte Inc (NASDAQ: PCVX) shares accounts for 107.92% of the company’s 128.76M shares outstanding.
It has a market capitalization of $4.86B and a beta (3y monthly) value of 1.02. The earnings-per-share (ttm) stands at -$3.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.94% over the week and 5.76% over the month.
Analysts forecast that Vaxcyte Inc (PCVX) will achieve an EPS of -0.92 for the current quarter, -0.97 for the next quarter and -4.72 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.03 while analysts give the company a high EPS estimate of -1.03. Comparatively, EPS for the current quarter was -0.85 a year ago. Earnings per share for the fiscal year are expected to decrease by -18.98%, and -2.74% over the next financial year. EPS should grow at an annualized rate of -5.58% over the next five years, compared to -29.88% over the past 5-year period.
Looking at the support for the PCVX, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on December 20, 2024, with the firm’s price target at $135. Mizuho coverage for the Vaxcyte Inc (PCVX) stock in a research note released on December 07, 2023 offered a Buy rating with a price target of $69. TD Cowen was of a view on April 18, 2023 that the stock is Outperform, while Needham gave the stock Buy rating on January 03, 2023, issuing a price target of $52- $58. Guggenheim on their part issued Buy rating on December 15, 2022.
